18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment : a phase 2 trial.

Vandenberghe, Rik;Van Laere, Koen;Ivanoiu, Adrian;Salmon, Eric;Brooks, David J;et.al.
(2010) Annals of Neurology — Vol. 68, n° 3, p. 319-329 (2010)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 289.18 KB
Request a copy

Details

Authors
  • Vandenberghe, Rik
    Author
  • Van Laere, Koen
    Author
  • Ivanoiu, AdrianUCLouvain
    Collaborator
  • Salmon, Eric
    Author
  • Brooks, David J
    Author
Show more
Abstract
The most widely studied positron emission tomography ligand for in vivo beta-amyloid imaging is (11)C-Pittsburgh compound B ((11)C-PIB). Its availability, however, is limited by the need for an on-site cyclotron. Validation of the (18)F-labeled PIB derivative (18)F-flutemetamol could significantly enhance access to this novel technology.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Vandenberghe, R., Van Laere, K., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., Minthon, L., Garraux, G., Nelissen, N., Bormans, G., Buckley, C., Owenius, R., Thurfjell, L., Farrar, G., & Brooks, D. J. (2010). 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment : a phase 2 trial. Annals of Neurology, 68(3), 319-329. https://doi.org/10.1002/ana.22068 (Original work published 2010)